The purpose of this study is to determine whether treatment with a drug called mavacamten reduces shortness of breath and fatigue and increases exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). Study procedures include review of medical history and medications, physical exams, blood draws, echocardiograms, cardiopulmonary exercise test, electrocardiograms, and questionnaires. Participants will be randomly assigned to receive either mavacamten capsules or placebo (inactive substance) capsules. Mavacamten has been approved by the U.S. Food and Drug Administration (FDA) in adults with obstructive hypertrophic cardiomyopathy (oHCM), but it is not approved for people with nHCM.
What is the full name of this clinical trial?
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Cardiomyopathy - non-obstructive hypertrophic (nHCM)